Health ❯ Healthcare ❯ Chronic Conditions

Type 2 Diabetes

Management Strategies Medication Management Weight Management Treatment Options Weight Loss Medications Obesity GLP-1 Medications Hypertension Diabetes Management Insulin Resistance

Mounjaro Study Finds Lower Heart‑Attack Risk as UK Safety Reports Rise

Officials say Yellow Card reports do not prove drugs caused harm.

Study Finds Small Increase in Optic‑Nerve Injury With GLP‑1 Diabetes Drugs

Meta-Analysis Finds Tirzepatide Produces Largest Average Weight Loss Among FDA‑Approved GLP‑1s

Cigna Drops GLP-1 Weight-Loss Coverage for Its Employees

Genetic Clues Help Explain GLP‑1 Differences in Results

FDA Approves Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes

Heart Risks Rebound After GLP-1 Breaks, New Data Show Continuous Use Is Safest

Vanderbilt Study Maps 70 Conditions That Precede Alzheimer’s by a Decade

UK Regulator Adds Severe Pancreatitis Warning to Ozempic, Wegovy and Mounjaro

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Lilly Taps Walmart for First Retail Pickup of Discounted Zepbound Vials Starting Mid-November

EMA Approves Cardiovascular Indication for Novo Nordisk’s Rybelsus

NHS Orders 55,000 Diabetes Retests After Faulty Lab Machines Trigger False Results

UK Regulator Probes Pancreatitis Cases Tied to GLP-1 Weight-Loss Therapies

Novo Nordisk’s Amycretin Delivers Up to 24% Early Weight Loss in Dual-Form Trials

NHS Weight-Loss Jab Prescriptions Near Three Million as Experts Raise Lifelong Use Concerns

Scotland Faces Health Crisis Linked to Weight-Loss Injections

Pharmacists Warn Against Fake Weight-Loss Jabs Amid Ozempic Shortage

FDA Issues Warning on Overdoses from Compounded Semaglutide Injections